A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Ramelteon (Primary)
- Indications Bipolar I disorders
- Focus Registrational; Therapeutic Use
- 18 Sep 2012 New trial record